The inhibition of p38 MAPK utilising oxalic amides attached to an azaindole scaffold

Bibliography

• DINARELLO CA: Inflammatory cytokines : interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr. Opin. Immunol. (1991) 3:941–948.
   PubMedGoogle Scholar
• PALLADINO MA, BAHJAT FR, THEODORAKIS EA, MOLDAWER LL: Anti-TNF-a therapies: the next generation. Nat. Rev. Drug Discov. (2003) 2:736–746.
   PubMed Web of Science ®Google Scholar
• •A good review of cytokines in inflammatory diseases.
   Google Scholar
• PARGELLIS C, REGAN J: Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Invest. Drugs (2003) 4:566–571.
   PubMedGoogle Scholar
• KOCH AE, KUNKEL SL, STRIETER RM: Cytokines in rheumatoid arthritis. J. Investig Med. (1995) 43:28–38.
   PubMed Web of Science ®Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. New England I Med. (1999) 340:1398–1405.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS PJ: Review article: efficacy of infliximab in Crohn's disease-induction and maintenance of remission. Alimentary Pharm. Ther. (1999) 13\(Supp1.4):9–15.
   Google Scholar
• BRESNIHAN B: The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Biodrugs. (2001) 15:87–97.
   Google Scholar
• JARVIS B, FAULDS D: Etanercept: a review of its use in rheumatoid arthritis. Drugs (1999) 57:945–966.
   PubMed Web of Science ®Google Scholar
• KUMAR S, BOEHM J, LEE JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. (2003) 2:717–726.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of the p38 MAPkinase field.
   Google Scholar
• PEARSON G, ROBINSON F, BEERS GT et al.: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrinol Rev. (2001) 22:153–183.
   PubMed Web of Science ®Google Scholar
• TIBBLES LA, WOODGETT JR: The stress-activated protein kinase pathways. Cell. MoL Life Sci. (1999) 55:1230–1254.
   PubMed Web of Science ®Google Scholar
• ONO K, HAN J: The p38 signal transduction pathway. Activation and function. Cell. Signal. (2000) 12:1–13.
   PubMed Web of Science ®Google Scholar
• LEE JC, KASSIS S, KUMAR S, BADGER A, ADAMS JL: p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther. (1999) 82:389–397.
   PubMed Web of Science ®Google Scholar
• SALITURO FG, GERMANN UA, WILSON KP, BEMIS GW, FOX T, SUMS: Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. (1999) 6:807–823.
   PubMed Web of Science ®Google Scholar
• COURT NW, DOS REMEDIOS CG, CORDELL J, BOGOYEVITCH MA: Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3). j MoL Cell Cardiol (2002) 34:413–426.
   Google Scholar
• JIANG Y, CHEN C, LIZ et al: Characterization of the structure and function of a new mitogen-activated protein kinase (p3813). J. Biol. Chem. (1996) 271:17920–17926.
   PubMed Web of Science ®Google Scholar
• JACKSON PF, BULLINGTON JL: Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Topics Med. Chem. (2002) 2:1009–1018.
   Google Scholar
• •An up-to-date review of the diaryl imidazole-based scaffolds used as p38 MAP kinase inhibitors.
   Google Scholar
• CIRILLO PF, PARGELLIS CA, REGAN J: The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Topics Med. Chem. (2002) 2:1021–1035.
   PubMedGoogle Scholar
• •A thorough review of alternate scaffolds that inhibit p38 MAP kinase.
   Google Scholar
• BADGER AM, GRISWOLD DE, KAPADIA R et al.: Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. (2000) 43:175–183.
   PubMed Web of Science ®Google Scholar
• MA XL, KUMAR S, GAO F et ell.: Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation (1999) 99:1685–1691.
   Google Scholar
• BEHR TM, NERURKAR SS, NELSON AH et al: Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation (2001) 104:1292–1298.
   PubMed Web of Science ®Google Scholar
• BARONE FC, IRVING EA, RAY AM et al: SB-239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. Pharmacol Exp. Ther. (2001) 296:312–321.
   PubMed Web of Science ®Google Scholar
• JU H, NERURKAR S, SAUERMELCH CF et al.: Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury. J. Pharmacol Exp. Ther. (2002) 301:15–20.
   Google Scholar
• FIJEN JW, ZIJLSTRA JG, DE BOER P et al.: Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol (2001) 124:16–20.
   Google Scholar
• FULLERTON T, SHARMA A, PRABHAKAR U et al.: Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 MAP kinase. Clin. Pharmacol Ther. (2000) 67:114 Abstract 0I-B–4.
   Google Scholar
• BRANGER J, VAN DEN BLINK B, WEIJER S et al.: Anti-inflammatory effects of a p38 mitogen activated protein kinase inhibitor, BIRB 796 BS, during human endotoxemia. j Immunol (2002) 168:4070–4077.
   Google Scholar
• BRANGER J, VAN DEN BLINK B, WEIJER S et al.: Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood (2003) 101:4446–4448.
   Google Scholar
• GOLDSTEIN D: The discovery of R 03201195, a novel and selective inhibitor of p38 kinase. Fifth World Conference on Inflammation. Edinburgh, Scotland. (September 22–262001) Abstract 12/02.
   Google Scholar
• FERRACCIOLI GF: VX-745 Vertex Pharmaceuticals. Curr. Opin. Antiinflam. Immunomod. Invest. Drugs (2000) 2:74–77.
   Google Scholar
• LU Q: Discovery and biological evaluationof p38 MAP kinase inhibitor SX-011. 228th American Chemical Society Meeting. Philadelphia, PA. (August 22–26 2004) MEDI 217.
   Google Scholar